Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes

PURPOSE: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs) have demonstrated efficacy in treating advanced non-small-cell lung cancer (NSCLC). Preliminary findings suggested that EGFR–TKIs might also be beneficial in neoadjuvant therapy in treating NSCLC. Therefore, this study...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Wang, Tao, Liu, Yang, Zhou, Bin, Wang, Zhi, Liang, Naichao, Zhang, Yundong, Dong, Zhouhuan, Li, Jie
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4809345/
https://ncbi.nlm.nih.gov/pubmed/27042123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S93823
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars